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Abstract 
Hemoglobin (Hb) adducts of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB), a metabolite of two 
tobacco-specific nitrosamines: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N’-
nitrosonornicotine (NNN), were measured in blood samples collected from 47 non-smokers, 
including 21 cases of lung cancer, enrolled in four centers. Exposure to environmental tobacco 
smoke (ETS) during the previous year from the spouse and at the workplace was assessed 
through questionnaire. Non-smokers exposed to ETS had a lower and non-significant level of 
HPB-Hb adducts than unexposed non-smokers (medians 15.8 and 20.1fmol/g Hb, p-value of the 
difference 0.32). Adjustment for age, sex, center and lung cancer case-control status had no 
effect on the results. Our results appear not to support the use of HPB-Hb adduct level as a 
marker of exposure to ETS in non-smokers. The conclusion drawn is however based on a small 
number of subjects and might suffer from exposure misclassification. 
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Abbreviations: Hb, hemoglobin; ETS, environmental tobacco smoke; HPB, 4-hydroxy-1-(3-pyridyl)-1- butanone; 
NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone;  NNN, N’-nitrosonornicortine;  OR, odds ratio;  Cl, 95% 
confidence interval.  
 













Exposure to environmental tobacco smoke (ETS) 
has been associated with increased risk of lung 
cancer (7). ETS contains measurable amounts of 
human carcinogens, many of which have been 
shown to covalently bind to DNA (4). A 
methodological problem in the study of exposure 
to ETS is the lack of a sensitive and reliable 
indicator for the biologically effective dose. The 
biologically effective dose reflects the amount of 
carcinogen that had interacted with DNA. A 
proposed solution to this problem is the 
application of analytical methods that measure the 
binding of tobacco-specific carcinogens to 
macromolecules such as DNA or proteins. 
 
The analytical method applied in this study 
measures the level of adducts with hemoglobin 
(Hb) of 4-hydroxy-1- (3-pyridyl)-1-butanone 
(HPB) (1). HPB is a common metabolite of two 
nitrosamines found only in tobacco:  4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) and nitrosonornicotine (NNN). NNK is a 
potent pulmonary carcinogen in rodents (9). Both 
nitrosamines might be important in human lung 
carcinogenesis (3). HPB has not been detected as a 
metabolite of other nitrosamines. Therefore, HPB 
should provide a specific marker for the metabolic 
activation of NNK and NNN (9). Although the 
persistence of HPB-Hb adducts has not been 
adequately determined in humans, studies have 
estimated that that Hb adducts of the aromatic 
amine 4-aminobiphenyl, also formed as a result of 
exposure to tobacco smoke, has a half-life of 
seven to nine weeks in humans (10,11). Thus the 
concentration of HPB released from Hb should 
give an indication of the amount of tobacco-
specific nitrosamines, NNK and NNN, to which an 
individual has been exposed during the last few 
months.  
 
Previous studies from the United States (3,6) and 
Germany (5,14) have shown that smokers have a 
higher level of HPB-Hb adducts than non-
smokers.  Although a transitional study was 
conducted (15) with the aim to assess the potential 
role of HPB-Hb adducts as a marker of the 
biologically effective dose of ETS in non-smokers, 
no data is currently available on the level of this 
biomarker in non- smokers exposed to ETS. 
 
MATERIALS AND METHODS 
 
For this analysis, 47 human subjects from four 
countries (Sweden, Russia, Romania and 
Germany) were selected within the framework of a 
multi-center, collaborative study on genetic 
alterations and susceptibility to lung cancer among 
non-smokers. Twenty-one had been diagnosed of 
having primary lung cancer, 12 were hospital 
patients with a disease not related to tobacco 
smoking, and the remaining 14 participants were 
apparently healthy subjects. 
 
All participants were interviewed using a standard 
questionnaire designed to gather information on 
active smoking, ETS exposure during childhood 
and adulthood, as well as occupational exposures, 
residential history and family history of cancer. 
Non-smokers were designated as subjects not 
having smoked more than one cigarette per day 
during one year (or approximately 400 cigarettes 
during life), or the equivalent as cigars, cigarillos 
and pipe tobacco. The questionnaire on ETS was 
validated using measurement of urinary cotinine 
(13). We considered regular exposure to ETS 
during the previous year. We restricted the 
analysis to exposure from the spouse and at the 
workplace, the two main sources of ETS identified 
in a previous validation study (13).  Quantitative 
information on exposure to ETS from the spouse, 
expressed as a number of cigarette smoked in the 
presence of the study subject were collected. 
 
Details of the assay used in the analysis of HPB-
Hb adducts from red blood cells (RBC) have been 
published previously (13). Briefly, a 30-ml blood 
sample was collected from study subjects; white 
blood cells, red blood cells and plasma were 
separated and frozen at –800C in each 
collaborating center. After thawing of the samples, 
Hb was purified by dialysis and HPB was released 
from Hb under alkaline conditions. After clean up 
with solid-phase extraction, the HPB-
pentafluorobenzoate derivative was formed before 
quantification by gas chromatography/negative ion 
chemical ionization mass spectrometry. The 
amount of HPB released from a particular sample 
of Hb was expressed as the amount of HPB in 
fentimol (fmol) divided by the amount of Hb in 
the samples in grams. The detection limit for HPB 
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was 1 pg HPB/injection or about 9 fmol HPB/g 
Hb, depending on the amount of Hb in the 
particular sample analyzed. The coefficient of 
variation of reproducibility of paired aliquots from 
the same sample ranged between 7% and 25%, the 
within-sample reproducibility of 4 and 8 aliquots 
was 4% and16% (13). 
 
For 25 subjects for whom duplicate samples were 
analyzed, the mean of two values was recorded as 
the subject whose adduct levels were at or below 
the method’s detection limit (9 fmol HPB/g Hb), 
the detection limit value was used for statistical 
analysis. Mean and median HPB-Hb adduct values 
were calculated for groups of subjects defined 
according to ETS exposure, and presence of lung 
cancer. Differences between groups were 
determined using non-parametric (Kruskal-Wallis 
and Mann-Whitney) tests. In addition, multivariate 
linear regression analysis was conducted to assess 
the contribution of ETS exposure on (log 
transformed) HPB-Hb adducts level after 
controlling for other possible determinants of 
adducts. A statistical package (16) was used to 




The mean age of study subjects was 62.0 (range 
34-84).  The overall mean value of HPB-Hb 
adducts was 19.8±7.8 fmol/g Hb (median 19.5 
fmol/g Hb). Table 1 shows the median adducts 
levels by age, gender, center and presence of lung 
cancer. There were small, non- significant 
differences in adduct level according to age, lung 
cancer, status and center. A total of 13 subjects 
reported regular exposure to ETS during the last 
year: 6 from the spouse and 7 at the workplace. 
Table 2 shows the results of the comparison 
between non-smokers exposed to ETS and 
unexposed non-smokers. HPB-Hb adduct levels 
were non-significantly lower in ex-smokers and 
never smokers than in current smokers. The results 
of multiple linear regression analysis, which 
included adjustment for age, sex, center, and 
presence of lung cancer were similar to those 
reported in Table 2; the regression coefficient for 
ETS exposure was –0.15 (standard error 0.14, 
p=0.29). We had quantitative information on ETS  
 
Table 1: Median level of HPB-Hb adducts (fmol/g Hb)  
according to age, gender, center and presence of lung 
cancer. 








Age group    
<60 18 15.3  
60-69 18  17.8  
70+ 11 23.4 0.20 
Gender    
Male  9 16.0  
Female 38 19.9 0.90 
Center    
Sweden 
11 23.0  
Germany 9 24.8  
Russia 12 19.9  
Romania 15 15.9 0.22 
Presence of 
lung cancer 
   
No 26 15.9  
Yes 21 21.2 0.38 
∗ Two-sided p-value based on Mann-Whitney or  
Kruskal-Wallis test. 
 
exposure among subjects exposed to ETS from the 
spouse (N=6): there was no correlation between 
ETS exposure and HPB-Hb adduct level (p-value 
of Spearman correlation coefficient 0.50). 
 
Table 2: Median and mean of HPB-Hb adducts (fmol/g Hb) according to exposure to environmental tobacco smoke∗ 
 No. of subjects Median Mean Standard deviation p-value of difference∗∗ 
No exposure 34 20.1 20.6 8.1  
Exposure 13 15.8 17.8 7.0 0.32 




This transitional study addresses the possible role 
of Hb adducts formed by tobacco-specific 
nitrosamines as a biological marker of exposure to 
ETS. Since HPB is a metabolite of two 
nitrosamines found only in tobacco smoke, NNK 
and NNN we hypothesized that HPB-Hb adducts 
might be useful to integrate low-level of exposure 
to tobacco smoke. Our results indicate that HPB-
Hb levels are slightly lower in non-smokers 
exposed to ETS than in unexposed non-smokers. 
 
Previous studies on HPB-Hb adducts as a marker 
of tobacco smoking revealed a contrast between 
smokers and non-smokers. Foiles and co-workers 
(6) found higher mean levels of HPB-Hb adducts 
in 100 smokers (163 fmol/g Hb) and 37 non- 
smokers (68±26 fmol/g Hb) in the United States. 
Two additional studies conducted in volunteers 
and pregnant women in Germany showed mean 
levels in smokers and non-smokers similar to 
those of the American study (5,14). A direct 
comparison with our results is complicated due to 
lack of a standard definition of non-smoker, and of 
the lack of data on the age distribution and source 
of enrollment of the subjects in these previous 
studies. It is unlikely however that these factors 
explain completely the differences between our 
results and those of previous studies. During 
method validation, we measured HPB-Hb adduct 
levels in blood samples taken at random from the 
general population to validate our method (1), and 
the results were comparable to those reported in 
previous studies. We think therefore that the lower 
level among non-smokers in this study as 
compared to previous studies are not explained by 
differences in the assay used to quantify HPB-Hb 
adduct levels. The more stringent definition of 
non-smokers in this study might be an explanation. 
In addition, it is possible that the lower level 
reflects decay of adducts during storage of 
samples. The samples analyzed in this study were 
stored for approximately one year at –800C, while 
samples analyzed in previous studies have been 
mainly stored for a short period. 
 
An innovative part of our study was the attempts 
to correlate HPB-Hb adduct level with ETS 
exposures in non-smokers. We found a non- 
significant decrease in adduct level in non-
smokers exposed to ETS as compared to 
unexposed non-smokers. We assessed ETS 
exposure via a standardized questionnaire which 
was validated against urinary cotinine levels (13) 
and was used in a study in which an association 
was shown between ETS exposure and lung 
cancer risk (2). In this study, attention was 
concentrated on ETS exposure from the spouse 
and at the workplace, which are the main 
predictors on urinary or serum cotinine in non-
smokers (12,13). However, we did not have 
information on very recent exposure to tobacco 
and ETS and the analysis was based on reported 
yearly exposure, which might have resulted in 
non-differential misclassification of exposure. 
Lack of sensitivity of the assay to detect the small 
effect, if any, of ETS on HPB-Hb adducts and 
limited statistical power are additional possible 
explanations for our findings. 
 
It could imply that a higher level of HPB-Hb 
adducts is a marker of susceptibility to tobacco 
carcinogenesis. NNK and NNN are compounds 
strongly suspected to be responsible for at least 
part of the carcinogenic properties of tobacco 
smoke. NNK is highly carcinogenic to the rodent 
lung, and causes cancer in rats, hamsters and mice 
independent on the route of administration, and 
NNN is an important esophageal carcinogen in 
rodents (8). It should also be considered that 
estimation of DNA adduct levels formed by 
tobacco-specific nitrosamines from Hb adduct 
levels is complex (10), as Hb adduct levels do not 
exactly reflect DNA adduct levels and, 
consequently, possible DNA damage. Such 
misclassification, however, would result in an 
underestimation of the association between DNA 
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